



SmartPA Criteria Proposal

| | |
|-----------------------------------|--|
| Drug/Drug Class: | Thrombocytopenia Agents PDL Edit |
| First Implementation Date: | April 4, 2019 |
| Revised Date: | October 5, 2023 |
| Prepared For: | MO HealthNet |
| Prepared By: | MO HealthNet/Conduent |
| Criteria Status: | <input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria |

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: The agents for thrombocytopenia vary in their mechanism of action, but all agents in this class increase platelet count. The approved indications vary among agents. Romiplostim, eltrombopag, fostamatinib, and avatrombopag are approved for the treatment of chronic immune thrombocytopenia (ITP) in adults (and children ≥ 1 year for eltrombopag and romiplostim) after insufficient response to corticosteroids, immunoglobulins, or splenectomy. Avatrombopag and lusutrombopag are approved for short-term use (5 to 7 days) in patients with chronic liver disease who are scheduled to undergo a procedure. Eltrombopag is also approved in patients with thrombocytopenia who require interferon-based therapy for hepatitis C and patients with severe aplastic anemia. These agents have not been directly compared to each other.

Total program savings for the PDL classes will be regularly reviewed.

| | | |
|--------------------------------------|---|--|
| Program-Specific Information: | Preferred Agents | Non-Preferred Agents |
| | <ul style="list-style-type: none">• NPlate®• Promacta® | <ul style="list-style-type: none">• Doptelet®• Mulpleta®• Tavalisse® |

Type of Criteria: ☐ Increased risk of ADE
☒ Appropriate Indications

☒ Preferred Drug List
☐ Clinical Edit

Data Sources: ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Thrombocytopenia Agents
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- For documented diagnosis of chronic immune thrombocytopenia:
 - Approvable agents: Doptelet, NPlate, Promacta, or Tavalisse **AND**
 - Adequate therapeutic trial of a corticosteroid (defined as 30 out of 60 days) **AND**
 - For Tavalisse or Doptelet:
 - Participants aged 18 years or older **AND**
 - Failure to achieve desired therapeutic outcomes with trial on 2 preferred agents **OR**
 - Documented ADE/ADR to preferred agents
 - For Promacta suspension: reason of medical necessity required for participants aged ≥ 10 years**
- For documented diagnosis of short-term use (5-7 days) in participants with chronic liver disease who are scheduled to undergo a procedure:
 - Approvable agents: Doptelet or Mulpleta

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosing limitation for the following:**

| Drug Description | Generic Equivalent | Max Dosing Limitation |
|-----------------------------|--------------------|-----------------------|
| PROMACTA 12.5 MG SUSPENSION | ELTROMBOPAG | 1 packet per day |
| PROMACTA 25 MG SUSPENSION | ELTROMBOPAG | 6 packets per day |
| PROMACTA 12.5 MG TABLET | ELTROMBOPAG | 1 tablet per day |
| PROMACTA 25MG TABLET | ELTROMBOPAG | 1 tablet per day |
| PROMACTA 50MG TABLET | ELTROMBOPAG | 2 tablets per day |
| PROMACTA 75MG TABLET | ELTROMBOPAG | 2 tablets per day |

Required Documentation

Laboratory Results: ☐
MedWatch Form: ☐

Progress Notes: ☐
Other: ☐

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine and Fiscal Analysis: "Therapeutic Class Review: HEMATOLOGIC AGENTS Thrombocytopenia Treatment Agents", Gainwell Technologies; Last updated May 10, 2023.
- Evidence-Based Medicine Analysis: "Thrombocytopenia Treatment Agents", UMKC-DIC; March 2023.
- USPDI, Micromedex; 2023.

SmartPA PDL Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.
Other company trademarks are also acknowledged.

- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.